Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
OpenAI Restricts Astra AI Over Cyberattack Risks 
VANCOUVER, British Columbia, March 05, 2018 -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, will report its financial results for the year ending December 31, 2017 and will provide a general business update on Monday March 12, 2018 after U.S. markets close.
Conference Call and Webcast Details:
Date: Monday March 12, 2018
Time: 4:30 PM (ET) / 1:30 PM (PT)
Toll-free: (866) 357-7878
International: (315) 625-3088
Audience Passcode 4665267
Webcast URL: https://edge.media-server.com/m6/p/9vvkbdes
The live webcast may be accessed through the "Events & Presentations" page in the "Investor Relations" section of the company's website at www.aqxpharma.com. The archived webcast will also be available on Aquinox's website approximately two hours after the event and will be available for replay for at least 30 days after the event.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is a first-in-class, once-daily, oral treatment with a novel mechanism of action, activating SHIP1 (SH2-containing inositol-5'-phosphatase 1), an enzyme that serves to down-regulate inflammation through its role in the PI3K signaling pathway. Rosiptor is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a debilitating condition marked by chronic bladder pain and urinary symptoms, for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Contact Info:
| Brendan Payne Associate Director, Investor Relations Aquinox Pharmaceuticals, Inc. 604.901.3019 [email protected] | Bill Kadel Vice President Solebury Trout 646.378.2934 [email protected] |
